Sud­den death forces Sophiris to halt fol­lowup ther­a­py in prostate can­cer study — shares crushed

Small-cap biotech Sophiris $SPHS has hit the brakes on its dos­ing sched­ule for pa­tients in its Phase IIb prostate can­cer study af­ter one of the sub­jects in the tri­al died short­ly af­ter re­ceiv­ing a sec­ond dose. 

There’s not much to go on here. 

Sophiris’ state­ment says on­ly that in­ves­ti­ga­tors study­ing top­salysin halt­ed any fur­ther sec­ond dos­es when one of the most re­cent pa­tients to get a sec­ond dose died on the same day. Ex­ecs not­ed the change-up af­ter tout­ing some of the re­spons­es they’ve been track­ing among a few dozen pa­tients in the tri­al. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER